Transaction Case Studies
Financing process for novel imaging technology achieves $20M Series C1
Situation Assessment
- Nanolive is a Swiss-based company that has developed and commercialized a non-invasive live cell imaging technology platform that stands to disrupt biopharma drug development
- Nanolive has sold 300+ imaging units worldwide to high-profile customers including marquee biopharma industry leaders
- Locust Walk developed investor materials and drove an outreach process aiming to achieve a successful Series C financing with dedicated life sciences investors
Key Activities
- Worked closely with company management and key board members to prepare investor outreach materials and identify investor targets from the Locust Walk global network
- Conducted targeted outreach to notable investors with a history or demonstrated interest in life sciences tools, including VCs, growth equity funds, family offices, corporate VCs, and strategics
- Ran several financial analyses to support investor discussions, including a comparable transaction analysis of M&A exits in life sciences tools, US biotech customer prospects, and IPO case studies
- Led numerous investors through due diligence, facilitating over 80 management presentations and diligence conversations while co-managing the CDA process and VDR access
- Guided Nanolive through deal dynamics and collaborated with management, co-lead investors, and legal teams to establish a timeline and drive the deal to final close
Successful Outcome
- Nanolive successfully completed a $20M Series C1 financing led by strong syndicate including new investor Taiwania Capital and existing investor Swisscom
- Funding enables Nanolive to further develop its AI-based digital assays solutions and accelerate the transition of its customer base from academic research labs to biopharma industry clients
